In 2013 Green and a team of researchers launched the BabySeq Project to study the ethical and medical consequences of sequencing a newborn´s DNA.
As of 2015, whole genome and exome sequencing as a newborn screening tool were deliberated. and in 2021, further discussed.
In 2021, the NIH funded BabySeq2, an implementation study that expanded the BabySeq project, enrolling 500 infants from diverse families and track the effects of their genomic sequencing on their pediatric care.
In 2023, the Lancet opined that in the UK "focusing on improving screening by upgrading targeted gene panels might be more sensible in the short term. Whole genome sequencing in the long term deserves thorough examination and universal caution."